Literature DB >> 8018414

Mutation analysis of RASK and the 'FLR exon' of NF1 in sporadic ovarian carcinoma.

W D Foulkes1, P Englefield, I G Campbell.   

Abstract

Frequent loss of heterozygosity has been described on several chromosomes in ovarian carcinoma (OC), but few tumour suppressor genes (TSGs) have been analysed. Mutations in the GTPase-related domain (GRD) of the TSG NF1 have been described in tumours not usually associated with neurofibromatosis type 1 (NF1). We analysed 36 OCs for mutations in this domain using single-strand conformation polymorphism. The NF1-GRD can downregulate the active form of p21RAS and, therefore, we analysed the same tumours for mutations in RASK. No cases of mutations in NF1-GRD were seen, and only two cases of RASK mutations were found. Thus, activation of the RAS signalling pathway by RASK or NF1 mutations does not appear to be common in OC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018414     DOI: 10.1016/0959-8049(94)90432-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.

Authors:  Kylie L Gorringe; David Yh Choong; Louise H Williams; Manasa Ramakrishna; Anita Sridhar; Wen Qiu; Jennifer L Bearfoot; Ian G Campbell
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

2.  Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21.

Authors:  M Tavassoli; H Steingrimsdottir; E Pierce; X Jiang; M Alagoz; F Farzaneh; I G Campbell
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

3.  Loss of heterozygosity on chromosome 22 in ovarian carcinoma is distal to and is not accompanied by mutations in NF2 at 22q12.

Authors:  P Englefield; W D Foulkes; I G Campbell
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.